Provider review
Alinwell Review: Four Peptides, and Lab Results Only for the GLP-1s
Alinwell's peptide menu is four products: tesamorelin at $299, sermorelin at $249, NAD+ at $199 and PT-141 at $249, each a monthly "from" price. The company does publish certificates of analysis that name the laboratory and the compounding pharmacy, but every one of them covers a GLP-1, and none covers a peptide. The peptide cards are careful about mechanism and quiet about who the evidence was gathered in.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit AlinwellOf Alinwell’s 4 dated product claims documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
A short, cleanly priced peptide menu from a company that shows lab results for its GLP-1s and none for the four peptides it sells.
Worth trusting if
- You want tesamorelin or PT-141, the two molecules here with completed phase 3 trials behind them
- You want the peptide price visible before any questionnaire
- You want a short menu of four products rather than a long list of blends
Be skeptical if
- You want a certificate of analysis for the peptide you are buying, which Alinwell publishes only for its GLP-1s
- You want to know which pharmacy compounds your peptide
- You fall outside the population a card's evidence came from, as most tesamorelin and male PT-141 buyers do
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Alinwell
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin — Priced twice on Alinwell's own site: $249/mo on the peptides page and $349/mo on the homepage, for the same product on the same day.
- NAD+ — Priced twice on Alinwell's own site: $199/mo on the peptides page against $249/mo on the homepage.
- Tesamorelin — $299/mo, quoted as a "from" floor rather than a rate. It is the dearest of the four peptides.
- PT-141 — $249/mo, quoted as a "from" floor.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 4 products reviewed here. The evidence concerns the molecule, not Alinwell's service.
4
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Alinwell’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
About the tesamorelin
SermorelinSermorelin · Compounded (503A)Claim matches the trials
“A GHRH analog that asks your own pituitary to release growth hormone on its natural nightly schedule — rather than replacing the hormone from outside.”
Read on the Alinwell site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery or sleep quality as an outcome in healthy adults. A parallel ClinicalTrials.gov search for sermorelin as an intervention returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
The card describes a mechanism, and the mechanism is exactly what sermorelin's trials measured. All 19 randomized trials record growth hormone secretion, growth in children or the response to a diagnostic challenge, so prompting the pituitary to release its own hormone is the tested part of this molecule. The product page goes further, with "May support recovery, body composition, and daytime energy over a course of use", and none of those three was an outcome in any of the 19 trials.1
NAD+NAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Not a peptide but a coenzyme your cells run on — NAD+ replenishes the electron-carrying fuel that quietly thins as the decades add up.”
Read on the Alinwell site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
The first half is accurate and unusually candid: NAD+ is a coenzyme, not a peptide, and Alinwell says so. The second half is the promise, that the product "replenishes" a supply that falls with age, and that is precisely what an injected-NAD+ trial would have to show. None has reported. The human literature usually offered concerns oral precursors, which are different molecules taken a different way.2
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“The stabilized GHRH analog studied specifically for the deep abdominal fat that resists diet and training.”
Read on the Alinwell site, September 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00123253 — Phase 3, completed, n=412. The pivotal trial of tesamorelin in HIV patients with excess abdominal fat. The outcome measured was visceral abdominal fat, in that population.
- NCT00608023 — Phase 3, completed, n=263. The extension study in the same HIV-associated lipodystrophy population.
The card is right that tesamorelin was studied for deep abdominal fat: both phase 3 trials measured visceral abdominal fat. It leaves out whose fat. Those trials enrolled adults with HIV-associated lipodystrophy, a specific medical condition, and "fat that resists diet and training" in a general adult is a different population. Nothing on the card or the product page tells a reader where the evidence was gathered.3,4
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“The peptide that starts in the brain rather than the bloodstream — PT-141 is studied for the melanocortin pathways tied to sexual desire, in women and men alike.”
Read on the Alinwell site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
The mechanism line is fair: bremelanotide acts on melanocortin receptors in the brain, and the card says "studied for" rather than "treats". The stretch is "in women and men alike". RECONNECT 1 and 2 enrolled 1,437 premenopausal women with hypoactive sexual desire disorder, and they are why an approved product exists. Men were not what those trials tested, and the page never mentions that an approved version of this molecule exists.5
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named for the peptides. Each peptide page says only that "Alinwell protocols are prepared by partner compounding pharmacies in the United States", and "503A" and "503B" appear nowhere on the site. Alinwell does name pharmacies elsewhere: the certificates of analysis on its semaglutide and tirzepatide pages were issued for Emerald Compounding Pharmacy in Tampa and Boudreaux's New Drug Store in Lake Charles. Those certificates cover GLP-1 batches, not peptides. Its terms also ask the buyer to "voluntarily and unconditionally waive your right to have the prescription filled at a pharmacy of your choice", a waiver in favor of a party the peptide pages never name.
Read on the Alinwell site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
Nothing is published for the peptides. The four peptide pages carry no certificate of analysis and no potency, purity or sterility result. The GLP-1 line is a different story: the semaglutide and tirzepatide pages sit under the heading "Every batch, independently lab-tested" and link four certificates, each with a batch number and a test month from early 2026, naming Emerald Compounding Pharmacy and Boudreaux's New Drug Store. A peptide buyer gets none of that. The testing Alinwell shows covers a different product line from the one reviewed here.
Read on the Alinwell site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Alinwell's FAQ says "Service is available across all 50 states", and its homepage banner reads "Telehealth nationwide". No list of states, and no exclusion, appears anywhere on the site.
Read the full licensing claim
"Reviewed by a licensed provider" and "Compounded in a U.S. pharmacy" at the top of the peptides page. No medical group, prescriber or state license number is published.
Read on the Alinwell site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- All four peptide prices are on a public page before any questionnaire, from $199 to $299 a month.
- The NAD+ card says plainly that NAD+ is "not a peptide but a coenzyme", which most sellers in this category blur.
- The sermorelin card describes a mechanism rather than an outcome, and that mechanism, the pituitary releasing its own growth hormone, is what the trials measured.
Show 4 more
- Tesamorelin and PT-141 are real molecules with completed phase 3 trials behind them.
- The company does publish certificates of analysis with batch numbers, test dates, the laboratory and the compounding pharmacy, even though they cover only its GLP-1s.
- Its disclaimer states plainly that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA.
- No FDA warning letter for the company.
- No certificate of analysis for any of the four peptides. The lab reports on the site cover semaglutide and tirzepatide only.
- No pharmacy is named for the peptides, which are described only as prepared by "partner compounding pharmacies in the United States".
- The tesamorelin card sells "the deep abdominal fat that resists diet and training" from trials run in adults with HIV-associated lipodystrophy, and never says so.
Show 6 more
- The PT-141 card says "in women and men alike", while the two phase 3 trials behind the approved product enrolled only women.
- The NAD+ card promises that it "replenishes" an age-depleted coenzyme, and no trial of injected NAD+ has reported that result.
- NAD+ and sermorelin are priced two different ways on the same site on the same day: $199 against $249, and $249 against $349.
- The peptide product pages still show "Other therapies to consider" cards for MOTS-C and BPC-157, and both lead to a page that does not exist.
- No prescriber or medical group is named anywhere, and the compounding class is never stated.
- Its terms ask you to waive the right to fill your prescription at a pharmacy of your choice.
Verdict
The bottom line
Alinwell's peptide line is four products at clear prices, and the cards are more restrained than most: sermorelin is described by the mechanism its trials measured, and NAD+ is honestly called a coenzyme. What the line lacks is anything to check. The lab reports on the site belong to the GLP-1s, the peptide pharmacy is unnamed, and two of the four cards draw on trials run in people unlike most buyers. If you want tesamorelin or PT-141, know whose evidence you are buying on.
Opens Alinwell's website. A link is not a recommendation to take anything.
What it sells
Alinwell's peptide menu is four products, each priced as a monthly "from" floor on the peptides page:
| Peptide | Price | What the card says |
|---|---|---|
| Tesamorelin | $299/mo | "The stabilized GHRH analog studied specifically for the deep abdominal fat that resists diet and training." |
| Sermorelin | $249/mo | "A GHRH analog that asks your own pituitary to release growth hormone on its natural nightly schedule…" |
| PT-141 | $249/mo | "…studied for the melanocortin pathways tied to sexual desire, in women and men alike." |
| NAD+ | $199/mo | "Not a peptide but a coenzyme your cells run on…" |
The homepage prices two of them differently. It lists NAD+ "from $249/mo" and sermorelin "from $349/mo", against $199 and $249 on the peptides page. Nothing on the site says which figure applies.
Each product page ends with an "Other therapies to consider" row that still offers MOTS-C and BPC-157. Both cards lead to a page that does not exist.
Full analysis — 3 more sectionsThe lab results cover the other product line · What the trials show · What is not published
The lab results cover the other product line
Alinwell's semaglutide and tirzepatide pages sit under the heading "Every batch, independently lab-tested." Each links two certificates of analysis with a batch number and a test month, issued for Emerald Compounding Pharmacy in Tampa and Boudreaux's New Drug Store in Lake Charles. That is more than most sellers show for anything.
None of it covers a peptide. The four peptide pages carry no certificate and no potency, purity or sterility result, and they name no pharmacy, only "partner compounding pharmacies in the United States". If you are buying tesamorelin or PT-141 here, the testing on the site tells you nothing about your vial.
What the trials show
Sermorelin is the card that holds up. It promises a mechanism, the pituitary releasing its own growth hormone, and that is what all 19 randomized trials measured, the newest from 2005. 1 The product page adds "recovery, body composition, and daytime energy", and none of those was an outcome in any of them.
Tesamorelin has the strongest record: two completed phase 3 trials, 675 participants between them. 3 Both studied adults with HIV-associated lipodystrophy, and the outcome was visceral abdominal fat in those patients. The card sells it for "deep abdominal fat that resists diet and training", which is a different population.
PT-141 rests on RECONNECT 1 and 2, 1,437 premenopausal women with hypoactive sexual desire disorder, and the basis of an FDA approval. 5 The card says "in women and men alike". The men's half was not what those trials tested, and the page never mentions the approved product.
NAD+ is honestly labeled a coenzyme rather than a peptide. The claim that an injection "replenishes" what declines with age has no reported trial behind it; the human research people cite concerns oral precursors, which are different molecules. 2
What is not published
No prescriber. No medical group. No pharmacy for the peptides. No compounding class: "503A" and "503B" appear nowhere on the site.
The terms go a step further than silence. Buying the service means you "voluntarily and unconditionally waive your right to have the prescription filled at a pharmacy of your choice", and prescriptions "may not use child-resistant packaging".
Questions
Frequently asked questions
Which peptides does Alinwell sell?
Four: tesamorelin from $299 a month, sermorelin from $249, PT-141 from $249 and NAD+ from $199. Alinwell also sells compounded GLP-1s, which are priced separately.
Does Alinwell publish test results for its peptides?
No. It publishes certificates of analysis for its semaglutide and tirzepatide batches, naming the laboratory and the compounding pharmacy, but the four peptide pages carry no certificate and no test result of any kind.
Which of its peptides has evidence behind it?
Tesamorelin and PT-141 have completed phase 3 trials, though both were run in specific populations: adults with HIV-associated lipodystrophy, and premenopausal women with hypoactive sexual desire disorder. Sermorelin reliably raises growth hormone, which is what its card claims. Injected NAD+ has no reported randomized trial.
Why is NAD+ priced two different ways?
Because Alinwell publishes two figures for it. The peptides page says $199/mo and the homepage says $249/mo, both live on the same day. Sermorelin does the same thing at $249 against $349. Nothing on the site reconciles either pair.
Which pharmacy compounds Alinwell's peptides?
It does not say. The peptide pages refer only to "partner compounding pharmacies in the United States". The pharmacies named on its GLP-1 certificates are Emerald Compounding Pharmacy and Boudreaux's New Drug Store, and nothing on the site says whether either one prepares the peptides. Its terms also ask you to waive the right to fill your prescription at a pharmacy of your choice.
Glossary
Key terms
Show definitions
- Certificate of analysis
- A laboratory report for one manufactured lot, giving identity, potency and sterility results against a specification. It describes the lot it was run on and says nothing about any other lot or any other product.
- GHRH analog
- A molecule that mimics growth-hormone-releasing hormone, signaling the pituitary to release its own growth hormone rather than supplying the hormone directly. Sermorelin and tesamorelin are both GHRH analogs.
- 503A
- The section of the Food, Drug, and Cosmetic Act covering a preparation compounded by a state-licensed pharmacy against a prescription for one named patient. Alinwell never uses this term, or 503B, anywhere on its site.
Compare
Others selling what Alinwell sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
- Pallas HealthAlso sells NAD+ (nicotinamide adenine dinucleotide) · 4 of 4 claims match the trials
- ShedAlso sells Sermorelin · 4 of 6 claims match the trials
- CareBareRXAlso sells NAD+ (nicotinamide adenine dinucleotide) · 2 of 4 claims match the trials
- EdenAlso sells Sermorelin · 3 of 6 claims match the trials
Ranked
The lists Alinwell is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Alinwell's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 5 sources
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine 357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Theratechnologies (2026). TH9507 in Patients With HIV-Associated Lipodystrophy, NCT00123253 — phase 3, completed, enrolment 412; and TH9507 Extension Study, NCT00608023 — phase 3, completed, enrolment 263. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- Kingsberg SA, Clayton AH, Portman D, Williams LA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology 134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.